After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...